Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1311-1320 Newer>

The Motley Fool July 16, 2004 Rich Duprey	aaiPharma's Headache Lingers The tiny pharmaceutical company regains its ticker symbol, but controversy still reigns. Facing a raft of class action lawsuits, shareholders may wonder whether samples of painkiller Darvon will be included with their annual reports
Bio-IT World July 14, 2004 Davies & Russell	The Sweet Hereafter Novartis' stunning new research home in a former candy factory is but one ingredient in a bold new recipe for success that embraces leadership, culture, science, and technology.
Bio-IT World July 14, 2004 Karen Hopkin	'Omics: The NextGeneration Researchers in industry and academia are cataloging collections of biochemical compounds (metabolomics) to determine how they respond when organisms are challenged by drugs, disease, or stress (metabonomics).
Bio-IT World July 14, 2004 Malorye A. Branca	The Pathways Promise By using the right tools, even a modest genomic data set can generate a good view into a particular biological pathway. Now, a range of new technologies is arising from academia as well as the commercial sector to meet this need.
Bio-IT World July 14, 2004 Laura Robinson	Signing On for Global Security This life sciences industry analyst for RSA Security, a developer of e-security technologies and products, discusses digital documentation and electronic signatures.
Bio-IT World July 14, 2004	The True Cost of Drug Discovery A new book with the provocative title "The $800 Million Pill" threatens to "strip away pharmaceutical industry spin" about the true cost of drug development.
BusinessWeek July 26, 2004 David Henry	Taking Encysive To Heart Buying into a company that bets heavily on a single new drug is dicey. But sometimes it's a risk worth taking.
The Motley Fool July 15, 2004 Brian Gorman	Research Company's Stock Surges PPD's (formerly Pharmaceutical Product Development) second-quarter report isn't perfect, but long-term indicators look solid. The stock has risen as much as 14%.
The Motley Fool July 13, 2004 Jeff Hwang	J&J Weathers Stent Duel The medical device and diagnostics business Johnson & Johnson delivers a solid second quarter despite competition from Boston Scientific's Taxus stent.
The Motley Fool July 13, 2004 Charly Travers	With Pfizer Drug, HIV Retreats Pfizer's newest HIV treatment shows promise in a demanding market.
<Older 1311-1320 Newer> Return to current articles.